Category: Research

Diamyd_logo

Diamyd US Phase III Study In Progress

Diamyd Medical announced it has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd or placebo...
0 Shares
xoma-logo

Two New Patents Issued to XOMA for Diabetes Drug

The California based bio-tech company XOMA announced that the U.S. Patent and Trademark Office has issued two new patents to XOMA as part of the company's expanding intellectual property portfolio around its XOMA 052 antibody to interleukin-1 beta (IL-1 beta)...
0 Shares
Lilly Logo

Eli Lilly Suspends Trials for New Type 1 Diabetes Drug

Eli Lilly and Co. and MacroGenics Inc. announced that the Protege Data Monitoring Committee (DMC), has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab. The DMC, composed of independent experts in the fields of diabetes and biostatistics, concluded that the primary efficacy endpoint of the study was not met...
0 Shares

Can Leptin Improve Blood Sugar Control in Type 1 Diabetics?

A clinical trial at UT Southwestern Medical Center aims to determine whether adding the hormone leptin to standard insulin therapy might help control the tumultuous blood-sugar levels of people with type 1 (insulin-dependent) diabetes...
0 Shares
Spherix Logo

Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug

Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes. The NEET (Naturlose® Efficacy Evaluation Trial) data showed a significant drop in Hemoglobin A1c (HbA1c) levels among patients treated with D-tagatose....
0 Shares
biodel logo

Biodel Presents New Study Results at EASD Annual Meeting

Biodel Inc. researchers presented results of a clinical study evaluating a new pH-neutral formulation of Linjeta(TM) (VIAject(R)) at the 46th annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm today. Dr. Tim Heise (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues reported that...
0 Shares